Inclusion criteria were: (1) original research articles in English, (2) experimental or clinical studies evaluating GLP-1 receptor agonists or related incretin-based compounds in Parkinson’s disease or PD models, and (3) studies reporting molecular, behavioural, or clinical outcomes. This evidence concerns the gene GCG and Parkinson disease.